A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort

Inclusion Criteria: * Subject is able and willing to provide informed consent and sign an informed consent form. * Subject must sign an authorization for the release of their protected health information. * Subject must be ≥50 and ≤85 years of age at the time of enrollment. * Subject must have hyperglycemia and/or diabetes as one of the following within 90 days prior to enrollment: * All glycemic parameters must be measured in an outpatient setting A. (1) Hemoglobin A1c (HbA1c) ≥ 6.5% present, OR B. Any (2) PDMs present on consecutive or simultaneous testing: * Fasting Blood Glucose (FBG) ≥126 mg/dl * Hemoglobin A1c (HbA1c) ≥ 6.5% * Random Blood Glucose (RBG) ≥200 mg/dl * 2h Post Glucose (PG) ≥200mg (11.1 mmol/L) during OGTT (oral glucose tolerance test), OR C. Any (1) PDM present followed by an anti-diabetes medication * Subject must have \>1 glycemic parameter measured in the 18 months prior to the elevated index lab without meeting inclusion criteria A, B, or C. * Subject must be willing to provide blood samples (fasting) at baseline, 6, 12, and 24 months post-enrollment. * Subject or authorized representative must be willing to complete a detailed questionnaire. Exclusion Criteria: * Subject must not have any past history of hyperglycemia and/or diabetes as defined by inclusion criteria A, B, or C * Transient diabetes (e.g. gestational and steroid-induced) is not an exclusion. * Subject must not be on active treatment for cancer, carry a current diagnosis of any cancer, and/or investigated for suspicion of recurrence of past cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix). * Ongoing work up for suspicion of pancreatic cancer is not an exclusion. * Subject must not have any past history of pancreatic cancer. * Subject must not be on anti-diabetes medications prior to the elevated index lab. * Subject must not be on chronic or acute use of steroid medications within 90 days of the elevated index lab. * Allowed: Nasal, topical steroids, oral budesonide, ophthalmic * Subject must not have had a recent (within 1 week of the elevated index lab) intra-articular steroid injection. * In the physician's and/or investigator's judgement, subject does not have any co-morbidities that limit the subject's participation in the study.